Recommendations on screening for type 2 diabetes in adults

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 15, 2012, Pages 1687-1696

  Pottie, Kevin ^a   Jaramillo, Alejandra ^b   Lewin, Gabriela ^a   Dickinson, Jim ^c   Bell, Neil ^d   Brauer, Paula ^e   Dunfield, Lesley ^b   Joffres, Michel ^f   Singh, Harminder ^g   Tonelli, Marcello ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF GUELPH   (Canada)

^f SIMON FRASER UNIVERSITY   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868143092     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.120732     Document Type: Article

References (51)

1. Public Health Agency of Canada. Diabetes in Canada: facts and figures from a public health perspective. Ottawa (ON): The Agency; 2011.
2. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.
3. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
4. Ur E, Chiasson JL, Ransom T, et al. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):14.
5. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva (Switzerland): The Organization; 2006. Available: www.who.int/diabetes/publications/ Definition%20and%20diagnosis%20of%20diabetes-new.pdf (accessed 2011 June 30).
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):62-9.
7. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Geneva (Switzerland): The Organization; 2011.
8. Goldenberg RM, Cheng AYY, Punthakee Z, et al. Position statement: use of glycated hemoglobin (A1c) in the diagnosis of type 2 diabetes mellitus in adults. Can J Diabetes 2011;35:247-9.
9. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.
10. Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36. (Pubitemid 43947203)
11. Vermeire E, Wens J, Van Royen P, et al. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(2):CD003638.
12. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
13. The Canadian Task Force on Preventive Health Care: procedure manual. Ottawa (ON): The Canadian Task Force on Preventive Health Care; 2011. Available: www.canadiantaskforce.ca/methods-manual-2011.html (accessed 2012 Sept. 10).
14. Connor Gorber S, Singh H, Pottie K. Process for guideline development by the reconstituted Canadian Task Force on Preventive Health Care. CMAJ 2012 Aug. 13 [Epub ahead of print]
15. Schünemann H, Brozek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Version 3.2 [updated March 2009]. GRADE Working Group; 2009. Available: www.who.int/hiv/topics/mtct/grade- handbook.pdf (accessed 2012 Sept. 10).
16. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74.
17. Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;17: iii-iv, ix-xi, 1-125.
18. Park P, Simmons RK, Prevost AT, et al. Screening for type 2 diabetes is feasible, acceptable, but associated with increased shortterm anxiety: a randomized controlled trial in British general practice. BMC Public Health 2008;8:350.
19. Eborall HC, Griffin SJ, Prevost AT, et al. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomized controlled trial. BMJ 2007;335:486.
20. Simmons RK, Echouffo-Tcheugui J, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): cluster-randomised controlled trial. Lancet. Epub 2012 Oct 3.
21. Hellgren MI, Petzold M, Björkelund C, et al. Feasibility of the FINDRISC questionnaire to identify individuals with impaired glucose tolerance in Swedish primary care. A cross-sectional population-based study. Diabet Med. Epub 2012 Mar 24.
22. Tankova T, Chakarova N, Atanassova I. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract 2011;92:46-52.
23. Simmons RK, Rahman M, Jakes RW, et al. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 2011;54:312-9.
24. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008;31: 1898-904.
25. Feig DS, Zinman B, Wang X, et al. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ 2008; 179:229-34.
26. Dyck R, Osgood N, Lin TH, et al. Epidemiology of diabetes mellitus among First Nations and non-First Nations adults. CMAJ 2010;182:249-56.
27. Spelman LM, Walsh PI, Sharifi N, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007;24:481-5. (Pubitemid 46669314)
28. Noble D, Mathur R, Dent T, et al. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011;343:d7163.
29. Lindström J, Absetz P, Hemio K, et al. Reducing the risk of type 2 diabetes with nutrition and physical activity - efficacy and implementation of lifestyle interventions in Finland. Public Health Nutr 2010;13(6A):993-9.
30. Robinson CA, Agarwal G, Nerenberg K. Validating the CANRISK prognostic model for assessing diabetes risk in Canada's multi-ethnic population. Chronic Dis Inj Can 2011;32:19-31.
31. Public Health Agency of Canada. The Canadian Diabetes Risk Assessment Questionnaire: CANRISK. Ottawa (ON): The Agency; 2009. Available: www.diabetes.ca/documents/for-professionals/NBI-CANRISK.pdf (accessed 2011 June 30).
32. Public Health Agency of Canada. Government of Canada gives Canadians tools to help detect diabetes risk. Ottawa (ON): The Agency; 2009; Available: www.phac-aspc.gc.ca/media/nr-rp/2009/2009-0318-eng.php (accessed 2011 June 30).
33. Kaczorowski J, Robinson C, Nerenberg K. Development of the CANRISK questionnaire to screen for prediabetes and undiagnosed type 2 diabetes. Can J Diabetes 2009;33:381-5.
34. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-31. (Pubitemid 36929335)
35. Colagiuri S, Vita P, Cardona-Morrell M, et al. The Sydney Diabetes Prevention Program: a community-based translational study. BMC Public Health 2010;10:328.
36. World Health Organization. HbA1c in the diagnosis of type 2 diabetes: a systematic review. Geneva (Switzerland): The Organization; 2011. Available: www.who.int/entity/diabetes/publications/sys-rev-hba1c-web.pdf (accessed 2012 Sept. 10).
37. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):11-61.
38. Canadian Agency for Drugs and Technologies in Health. Diabetes screening and diagnosis. Ottawa (ON): The Agency; 2009. Available: www.cadth.ca/index.php/ en/hta/reports-publications/health-technology-update/ht-update-12/ diabetes-screening-and-diagnosis (accessed 2011 June 30).
39. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000;23:1563-80.
40. Meltzer SJ, Snyder J, Penrod JR, et al. Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one-step and two-step methods. BJOG 2010;117:407-15.
41. Park P, Simmons RK, Prevost AT, et al.; ADDITION Cambridge study group. A randomized evaluation of loss and gain frames in an invitation to screening for type 2 diabetes: effects on attendance, anxiety and self-rated health. J Health Psychol 2010; 15: 196-204.
42. Thoolen BJ, de Ridder D, Besing J, et al. Psychological outcomes of patients with screen-detected type 2 diabetes: the influence of time since diagnosis and treatment intensity. Diabet Care 2005;29:2257-62.
43. Marteau TM, Mann E, Prevost AT, et al. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial. BMJ 2010;340:c2138.
44. Edelman D, Olsen MK, Dudley TK, et al. Impact of diabetes screening on quality of life. Diabetes Care 2002;25:1022-6. (Pubitemid 41110488)
45. Adriaanse MC, Snoek FJ, Dekker JM, et al. Screening for type 2 diabetes: an exploration of subjects' perceptions regarding diagnosis and procedure. Diabet Med 2002;19:406-11. (Pubitemid 34534216)
46. Adriaanse MC, Snoek FJ. The psychological impact of screening for type 2 diabetes. Diabet Metab Res Rev 2006;22:20-5. (Pubitemid 43154457)
47. Stewart-Brown S, Farmer A. Screening could seriously damage your health. BMJ 1997;314:533-4. (Pubitemid 27089368)
48. Feig DS, Palda VA, Lipscombe L; Canadian Task Force on Preventive Health Care. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2005;172:177-180.
49. American Diabetes Association. Executive summary: standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl 1):4-10.
50. Norris SL, Kansagara D, Bougatsos C, et al.; US Preventive Services Task Force. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2008;148:855-68. (Pubitemid 351786934)
51. National Institute for Health and Clinical Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk [public health guidance PH38]. London (UK): The Institute; 2012. Available: http://guidance.nice.org.uk/ph38 (accessed 2012 Oct. 10).